» Articles » PMID: 16887966

Mesenchymal Stem Cells Inhibit Generation and Function of Both CD34+-derived and Monocyte-derived Dendritic Cells

Overview
Journal J Immunol
Date 2006 Aug 5
PMID 16887966
Citations 283
Authors
Affiliations
Soon will be listed here.
Abstract

Mesenchymal stem cells (MSCs) are not only able to evade the immune system, but they have also been demonstrated to exert profound immunosuppressive properties on T cell proliferation. However, their effect on the initiators of the immune response, the dendritic cells (DCs), are relatively unknown. In the present study, the effects of human MSCs on the differentiation and function of both CD34+ -derived DCs and monocyte-derived DCs were investigated. The presence of MSCs during differentiation blocked the differentiation of CD14+CD1a- precursors into dermal/interstitial DCs, without affecting the generation of CD1a+ Langerhans cells. In line with these observations, MSCs also completely prevented the generation of immature DCs from monocytes. The inhibitory effect of MSCs on DC differentiation was dose dependent and resulted in both phenotypical and functional modifications, as demonstrated by a reduced expression of costimulatory molecules and hampered capacity to stimulate naive T cell proliferation. The inhibitory effect of MSCs was mediated via soluble factors. Taken together, these data demonstrate that MSCs, next to the antiproliferative effect on T cells, have a profound inhibitory effect on the generation and function of both CD34+ -derived and monocyte-derived DCs, indicating that MSCs are able to modulate immune responses at multiple levels.

Citing Articles

Improving the therapeutic profile of MSCs: Cytokine priming reduces donor-dependent heterogeneity and enhances their immunomodulatory capacity.

Valencia J, Yanez R, Muntion S, Fernandez-Garcia M, Martin-Rufino J, Zapata A Front Immunol. 2025; 16:1473788.

PMID: 40034706 PMC: 11872697. DOI: 10.3389/fimmu.2025.1473788.


Application of Mesenchymal Stem Cells in Female Infertility Treatment: Protocols and Preliminary Results.

Chatzianagnosti S, Dermitzakis I, Theotokis P, Kousta E, Mastorakos G, Manthou M Life (Basel). 2024; 14(9).

PMID: 39337944 PMC: 11433628. DOI: 10.3390/life14091161.


Adipose-derived mesenchymal stem cell therapy for connective tissue diseases and complications.

Kotani T, Saito T, Suzuka T, Matsuda S Inflamm Regen. 2024; 44(1):35.

PMID: 39026275 PMC: 11264739. DOI: 10.1186/s41232-024-00348-z.


Therapeutic and Safety Promise of Mesenchymal Stem Cells for Liver Failure: From Preclinical Experiment to Clinical Application.

Xie Q, Gu J Curr Stem Cell Res Ther. 2023; 19(10):1351-1368.

PMID: 37807649 DOI: 10.2174/011574888X260690230921174343.


A Supportive Role of Mesenchymal Stem Cells on Insulin-Producing Langerhans Islets with a Specific Emphasis on The Secretome.

Sionov R, Ahdut-HaCohen R Biomedicines. 2023; 11(9).

PMID: 37761001 PMC: 10527322. DOI: 10.3390/biomedicines11092558.